Molecular targeted therapy of hepatocellular carcinoma-results of the first clinical studies
MW Wiedmann, J Mossner - Current cancer drug targets, 2011 - ingentaconnect.com
Hepatocellular carcinoma (HCC) is a common cancer with poor prognosis and worldwide
rising incidence during the last years. Although orthotopic liver transplantation, surgical …
rising incidence during the last years. Although orthotopic liver transplantation, surgical …
Anti-tumour effects of transcatheter arterial embolisation administered in combination with thalidomide in a rabbit VX2 liver tumour model
A Nitta-Seko, N Nitta, A Sonoda, H Otani… - The British Journal of …, 2011 - academic.oup.com
Objective: Using a liver tumour model we investigated whether thalidomide enhances the
anti-tumour effect of transcatheter arterial embolisation (TAE). Method: First, the viability of …
anti-tumour effect of transcatheter arterial embolisation (TAE). Method: First, the viability of …
Induction Chemotherapy for Hepatocellular Carcinoma
T Fukumoto, Y Ku - … : Integrated Treatment Programs for Locally Advanced …, 2011 - Springer
Hepatocellular carcinoma (HCC) is known as a relatively chemoresistant tumor. Systemic
cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. Other …
cytotoxic chemotherapy has failed to show a substantial benefit for patients with HCC. Other …